BioCentury
ARTICLE | Clinical News

BB3: Ph II GUARD started

February 16, 2017 8:16 PM UTC

Angion began the double-blind, placebo-controlled, U.S. Phase II GUARD trial to evaluate 6 mg/mL IV BB3 daily for 4 days in about 100 patients who undergo open heart surgery and require the use of car...